Delving into the Latest Updates on Zucapsaicin with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

(Z)-Capsaicin, Civamide, Civanex

+ [6]

Target

TRPV1

Action

agonists

Mechanism

TRPV1 agonists(Transient receptor potential cation channel subfamily V member 1 agonists)

Therapeutic Areas

Immune System DiseasesNervous System DiseasesSkin and Musculoskeletal Diseases+ [1]

Active Indication

OsteoarthritisPainCluster Headache

Inactive Indication

Dry Eye SyndromesNeuralgia, PostherpeticOsteoarthritis, Knee+ [2]

Originator Organization

Winston & Strawn LLP

Active Organization

Winston Laboratories, Inc.

Inactive Organization-

License Organization-

Drug Highest PhaseApproved

First Approval Date

Canada (15 Jul 2010),

OsteoarthritisPain

RegulationOrphan Drug (United States)

Login to view timeline

Structure/Sequence

Molecular FormulaC18H27NO3

InChIKeyYKPUWZUDDOIDPM-VURMDHGXSA-N

CAS Registry25775-90-0

It is of considerable scientific and clinical importance to assess tobacco withdrawal accurately since withdrawal severity is highly determinant of smoking cessation success. In addition, smoking cessation pharmacotherapy produces its effects on smoking abstinence by suppressing such symptoms. However, in order to ensure that a measure of tobacco withdrawal is sensitive to severe withdrawal, it is essential to examine a period of unmedicated abstinence. The current study aims to validate, and possibly enhance, a revised Wisconsin Smoking Withdrawal Scale long and brief version for use in research and clinical settings.
Two hundred adults who smoke cigarettes daily and report a desire to quit smoking will be enrolled. This is a treatment-delay, one-group clinical trial that is intended to enhance the assessment of tobacco withdrawal amongst participants who try to quit smoking with delayed use of cessation medication. Participants will not receive any pharmacotherapy during the first 1 week of their quit attempt and will initiate 8 weeks of combination nicotine replacement therapy (C-NRT; nicotine patch + nicotine mini-lozenge) starting 1 week past the target quit day (TQD). Participants will receive 4 counseling sessions as well (1 pre-quit, 3 post-quit). Participants will complete 4 weeks of ecological momentary assessment (EMA) smartphone surveys including a 2-week baseline (starting TQD-14) and 2-week post-TQD (1-week un-medicated, 1-week using C-NRT).

Start Date13 Jul 2021

Sponsor / Collaborator

University of Wisconsin Madison

[+1]

NCT04169854

/ Unknown statusPhase 3IIT

Pre-emptive Topical Lidocaine 5% Plaster for Prevention of Post-craniotomy Pain : a Protocol for a Randomized, Triple Blind, Placebo-controlled Trail

Postcraniotomy pain remains a common phenomenon in the neurosurgery field. Managements for postcraniotomy pain are to be standardised and optimized. In the proposed study, the investigators aim to provide a novel regional non-invasive prophylactic strategy for postcraniotomy pain by utilizing Lidocaine 5% plaster.

Start Date15 Oct 2020

Sponsor / Collaborator

Beijing Tiantan Hospital

100 Clinical Results associated with Zucapsaicin

Login to view more data

100 Translational Medicine associated with Zucapsaicin

Login to view more data

100 Patents (Medical) associated with Zucapsaicin

Login to view more data

50

Literatures (Medical) associated with Zucapsaicin

01 Apr 2024·Archives of Biochemistry and Biophysics

Identifying novel aryl hydrocarbon receptor (AhR) modulators from clinically approved drugs: In silico screening and In vitro validation

Article

Author: Mosa, Farag E S ; El-Kadi, Ayman O S ; El-Ghiaty, Mahmoud A ; Alqahtani, Mohammed A ; Barakat, Khaled

The aryl hydrocarbon receptor (AhR) functions as a vital ligand-activated transcription factor, governing both physiological and pathophysiological processes. Notably, it responds to xenobiotics, leading to a diverse array of outcomes. In the context of drug repurposing, we present here a combined approach of utilizing structure-based virtual screening and molecular dynamics simulations. This approach aims to identify potential AhR modulators from Drugbank repository of clinically approved drugs. By focusing on the AhR PAS-B binding pocket, our screening protocol included binding affinities calculations, complex stability, and interactions within the binding site as a filtering method. Comprehensive evaluations of all DrugBank small molecule database revealed ten promising hits. This included flibanserin, butoconazole, luliconazole, naftifine, triclabendazole, rosiglitazone, empagliflozin, benperidol, nebivolol, and zucapsaicin. Each exhibiting diverse binding behaviors and remarkably very low binding free energy. Experimental studies further illuminated their modulation of AhR signaling, and showing that they are consistently reducing AhR activity, except for luliconazole, which intriguingly enhances the AhR activity. This work demonstrates the possibility of using computational modelling as a quick screening tool to predict new AhR modulators from extensive drug libraries. Importantly, these findings hold immense therapeutic potential for addressing AhR-associated disorders. Consequently, it offers compelling prospects for innovative interventions through drug repurposing.

01 Jul 2023·Radiation Physics and Chemistry

Determination of the molecular structure and spectroscopic properties of capsaicin

Author: Alim, Zuhal ; Sakar, Erdem ; Alim, Bunyamin ; Cinar, Mehmet

In this study, the ground state mol. structure and spectroscopic features of cis- and trans-forms of capsaicin were investigated using DFT (B3LYP) invoking 6-311++G(d,p) basis set.The optimized geometry of capsaicin was determined for the isolated mol. in a vacuum, and then the vibrational spectra (IR and Raman) obtained, and the assignments of fundamental vibrational modes were done.By applying the GIAO method, proton and carbon chem. shifts were computed for the gas and solvated phases.Besides using the TD-DFT, the Hirshfeld surface and Mol. electrostatic potential surfaces were obtained and evaluated to understand the electronic properties.The total and partial d. of state (TDOS and PDOS) spectra were also examinedAll obtained computational results were compared with the previously reported exptl. data.A high accuracy was obtained for the ground state geometrical structure, and thus, the vibrational frequencies especially lie on the finger print region are predicted also with a high correlation.Similarly, the optimization of chem. shift values calculated by considering solvent effects with exptl. data were found as high R² values of 0.9953 and 0.9455 for C and H atoms, resp.This comparison shows that the DFT method precisely predicts capsaicin′s mol. and spectroscopic characteristics.

10 Apr 2023·Journal of chemical information and modeling

Phyto4Health: Database of Phytocomponents from Russian Pharmacopoeia Plants.

Article

Author: Ionov, Nikita ; Poroikov, Vladimir ; Druzhilovskiy, Dmitry ; Filimonov, Dmitry

Medicinal plants growing in Russia are a rich source of biologically active compounds. However, the evaluation of the hidden pharmacological potential of these compounds by in silico methods is complicated by the lack of specialized databases. We have created a database of 3128 phytocomponents from 268 medical plants included in the Russian Pharmacopoeia. The information about the compounds was supplemented with their physical-chemical characteristics and biological activity profiles estimated using the PASS software. Comparison with phytocomponents of medicinal plants from five other countries showed that the similarity of phytocomponents in our database is rather small. The uniqueness of the contents significantly enriches and provides easy access to the necessary information. The Phyto4Health data are freely available at http://www.way2drug.com/p4h/.

100 Deals associated with Zucapsaicin

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D06388	Zucapsaicin	M02AB02	DB09120

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Osteoarthritis	Canada	-	15 Jul 2010
Pain	Canada	-	15 Jul 2010

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Trigeminal Neuralgia	Phase 1	United States	Winston Laboratories, Inc.	01 Mar 2014
Neuralgia, Postherpetic	Phase 1	Canada	Winston Laboratories, Inc.	01 Mar 2009
Neuralgia, Postherpetic	Phase 1	United States	Winston Laboratories, Inc.	01 Mar 2009
Dry Eye Syndromes	Preclinical	United States	Winston Laboratories, Inc.	01 May 2014
Neuralgia, Postherpetic	Preclinical	Canada	Winston Laboratories, Inc.	01 Mar 2009
Neuralgia, Postherpetic	Preclinical	United States	Winston Laboratories, Inc.	01 Mar 2009
Post-traumatic neuralgia	Preclinical	Canada	Winston Laboratories, Inc.	01 Mar 2009
Post-traumatic neuralgia	Preclinical	United States	Winston Laboratories, Inc.	01 Mar 2009
Osteoarthritis, Knee	Preclinical	-	Winston Laboratories, Inc.	01 Jun 2003
Cluster Headache	Preclinical	United States	Winston Laboratories, Inc.	01 Jan 2002

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04969198 (CTgov)	Phase 2	Acral Lentiginous Malignant Melanoma	232	Combination nicotine replacement therapy (Nicotine patch + nicotine mini-lozenge)	cctrnpwjab(aqmtpbowvp) = hbscynhgit tuhavsdfrg (xeehwrgics, nkuugcicnt - vvexavvgqj) View more	-	01 Dec 2023
NCT01592695 (CTgov)	Phase 2	Alcoholism \| Smoking \| Obesity	63	Combination pharmacotherapy - transdermal nicotine patch + nicotine gum+Nicotine replacement therapy - nicotine gum+Varenicline+Bupropion Sustained Release+Nicotine replacement therapy - transdermal nicotine patch (Tailored Intervention Group)	zwdbyxvtiw(udqdirvhoz) = rdjnlyiqvw swoeqzytsb (imtliwvswc, urdftubvmi - tsqgnupbto) View more	-	19 Jul 2017
				Combination pharmacotherapy - transdermal nicotine patch + nicotine gum+Nicotine replacement therapy - nicotine gum+Varenicline+Bupropion Sustained Release+Nicotine replacement therapy - transdermal nicotine patch (Enhanced Standard of Care Group)	zwdbyxvtiw(udqdirvhoz) = bdzgpqudix swoeqzytsb (imtliwvswc, hvtjtatpni - fyokgcdhua) View more
NCT01886313 (CTgov)	Phase 2	Neuralgia, Postherpetic \| Trigeminal Neuralgia	11	Civamide (Double Blind Treatment Period Civamide Nasal Spray)	bvnwzemkjk(qgmpnzlbom) = gifvuhhqdp dhymkfjnmq (hxbogypdux, pqfsvllwia - npksfngfem) View more	-	01 Mar 2017
				Placebo (Double Blind Treatment Period Placebo Nasal Spray)	bvnwzemkjk(qgmpnzlbom) = zxhxusocxu dhymkfjnmq (hxbogypdux, ygbqtbxued - ophorocjom) View more